English (United States)

About the MARITIME-2 study

MARITIME-2 is a Phase 3 study for people living with type 2 diabetes and overweight or obesity. In this study, we are exploring if an investigational medicine (a monthly injection) is safe to use, and whether it can help people with type 2 diabetes to lose weight and manage weight-related conditions.

Who can take part?

Amgen is currently recruiting for this trial.

You, or someone you care for, may be able to take part if you/they:

  • are 18 years of age or older,
  • are living with type 2 diabetes,
  • are living with overweight or obesity.

What will this study involve?

The MARITIME-2 study will last up to 88 weeks (a little under 2 years). Participants will receive either the investigational medicine or a placebo, which contains no actual medicine. A placebo looks the same as the investigational medicine.


The study is made up of 3 parts.

Screening period

(up to 4 weeks)

PARTICIPANT RESPONSIBILITIES:

  • Visit the study center to see if you meet the requirements of the trial

Study treatment period 


(about 72 weeks / 16.5 months)

PARTICIPANT RESPONSIBILITIES:

  • Visit the study center about 20 times for assessments
  • Receive the study drug or a placebo

Follow-up period




(about 12 weeks / 3 months)

PARTICIPANT RESPONSIBILITIES:

  • Visit the study center once more for study assessments